The receptor for urokinase-plasminogen activator (uPAR) controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style

Oncotarget

Volumn 5, Issue 6, 2014, Pages 1538-1553

  Margheri, Francesca ^a   Luciani, Cristina ^a   Taddei, Maria Letizia ^a   Giannoni, Elisa ^a   Laurenzana, Anna ^a   Biagioni, Alessio ^a   Chillà, Anastasia ^a   Chiarugi, Paola ^a   Fibbi, Gabriella ^a   del Rosso, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Amoeboid movement; Melanoma; Mesenchymal movement; Prostate carcinoma; Rho GTPases; uPAR

Indexed keywords

ACTIN; BETA1 INTEGRIN; BETA3 INTEGRIN; PEPTIDE; PROTEINASE INHIBITOR; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UROKINASE RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA;

ACTIN FILAMENT; AMOEBOID; ARTICLE; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL MOTION; CELL TRANSFORMATION; CELL TYPE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA CELL; MESENCHYMAL AMOEBOID TRANSITION; MESENCHYME CELL; PLASTICITY; PROSTATE CANCER CELL LINE; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURFACE; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; MELANOMA; MESODERM; METABOLISM; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING;

ACTIN CYTOSKELETON; ANTIGENS, CD29; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURFACE EXTENSIONS; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MELANOMA; MESODERM; NEOPLASM INVASIVENESS; PHENOTYPE; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 84904258144     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1754     Document Type: Article

References (48)

1. Friedl P, Wolf K. Plasticity of cell migration: a multiscale tuning model. J Cell Biol. 2010; 188: 11-19.
2. Friedl P. Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin. 2004; 16: 14-23.
3. Parri M, Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun Signal. 2010; 8: 23.
4. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol. 2003; 160: 267-277.
5. Sanz-Moreno V, Marshall CJ. Rho-GTPase signaling drives melanoma cell plasticity. Cell Cycle. 2009; 8: 1484-1487.
6. Nimnual AS, Taylor LJ, Bar-Sagi D. Redox-dependent downregulation of Rho by Rac. Nat Cell Biol. 2003; 5: 236-241.
7. Parri M, Taddei ML, Bianchini F, Calorini L, Chiarugi P. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 2009; 69: 2072-2081.
8. Cartier-Michaud A, Malo M, Charriere-Bertrand C, Gadea G, Anguille C, Supiramaniam A Lesne A, Delaplace F, Hutzler G, Roux P, Lawrence DA, Barlovatz-Meimon G. Matrix-bound PAI-1 supports cell blebbing via RhoA/ ROCK1 signaling. PLoS One. 2012; 7: e32204.
9. Del Rosso M, Margheri F, Serrati S, Chilla A, Laurenzana A, Fibbi G. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Curr Pharm Des. 2011; 17: 1924-1943.
10. Eden G, Archinti M, Furlan F, Murphy R, Degryse B. The urokinase receptor interactome. Curr Pharm Des. 2011; 17: 1874-1889.
11. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol Chem. 2002; 383: 5-19.
12. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem.1991; 266: 1926-1933.
13. Margheri F, Manetti M, Serrati S, Nosi D, Pucci M, Matucci-Cerinic M Kahaleh B, Bazzichi L, Fibbi G, Ibba-Manneschi L, Del Rosso M. Domain 1 of the urokinasetype plasminogen activator receptor is required for its morphologic and functional, beta2 integrin-mediated connection with actin cytoskeleton in human microvascular endothelial cells: failure of association in systemic sclerosis endothelial cells. Arthritis Rheum. 2006; 54: 3926-3938.
14. Xue W, Mizukami I, Todd RF, 3rd, Petty HR. Urokinasetype plasminogen activator receptors associate with beta1 and beta3 integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 1997; 57: 1682-1689.
15. Roca-Cusachs P, Iskratsch T, Sheetz MP. Finding the weakest link: exploring integrin-mediated mechanical molecular pathways. J Cell Sci, 2012; 125: 3025-3038.
16. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3: 362-374.
17. Yamazaki D, Kurisu S, Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci. 2005; 96: 379-386.
18. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G Parsons JT, Horwitz AR. Cell migration: integrating signals from front to back. Science. 2003; 302: 1704-1709.
19. Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Curr Pharm Des. 2011; 17: 1970-1978.
20. Margheri F, Schiavone N, Papucci L, Magnelli L, Serrati S, Chilla A Laurenzana A, Bianchini F, Calorini L, Torre E, Dotor J, Feijoo E, Fibbi G, Del Rosso M. GDF5 regulates TGFß-dependent angiogenesis in breast carcinoma MCF-7 cells: in vitro and in vivo control by anti-TGFß peptides. PLoS One. 2012 7: e50342.
21. Margheri F, D'Alessio S, Serrati S, Pucci M, Annunziato F, Cosmi L Liotta F, Angeli R, Angelucci A, Gravina GL, Rucci N, Bologna M, Teti A, Monia B, Fibbi G, Del Rosso M. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. Gene Ther. 2005; 12: 702-714.
22. Margheri F, Chilla A, Laurenzana A, Serrati S, Mazzanti B, Saccardi R Santosuosso M, Danza G, Sturli N, Rosati F, Magnelli L, Papucci L, Calorini L, Bianchini F,Del Rosso M, Fibbi G. Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. Blood 2011; 118: 3743-3755.
23. Del Rosso M, Fibbi G, Pucci M, Margheri F, Serrati S. The plasminogen activation system in inflammation. Front Biosci 2008; 13: 4667-4686.
24. Llinas P, Le Du MH, Gardsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Ménez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J. 2005; 24: 1655-1663.
25. Ploug M. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry. 1998; 37: 16494-16505.
26. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002; 277: 46932-46939.
27. Gupta A, Cao W, Chellaiah MA. Integrin alphavbeta3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-kappaB ligand signaling axis. Mol Cancer. 2012; 11: 66.
28. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting constitutively activated beta1 integrins inhibits prostate cancer metastasis. Mol Cancer Res. 2013; 11: 405-417.
29. Pisano M, I DEP, Nieddu V, Sassu I, Cossu S, Galleri G, Del Gatto A, Budroni M, Cossu A, Saviano M, Palmieri G, Zaccaro L, Rozzo C. In vitro activity of the alphavbeta3 integrin antagonist RGDechi-hCit on malignant melanoma cells. Anticancer Res. 2013; 33: 871-879.
30. Wang R, Bi J, Ampah KK, Zhang C, Li Z, Jiao Y, Wang X, Ba X, Zeng X.Lipid raft regulates the initial spreading of melanoma A375 cells by modulating beta1 integrin clustering. Int J Biochem Cell Biol. 2013; 45: 1679-1689.
31. Harbeck N, Schmitt M, Meisner C, Friedel C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, Hasmüller S, Kiechle M, Jänicke F, Thomssen C;Chemo-N 0 Study Group. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer. 2013; 49: 1825-1835.
32. Mazar AP, Henkin J, Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis. 1999; 3: 15-32.
33. Del Rosso M. uPAR in angiogenesis regulation. Blood 2011; 117: 3941-3943.
34. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol. 2007; 178: 425-436.
35. Asuthkar S, Stepanova V, Lebedeva T, Holterman AL, Estes N, Cines DB, Rao JS, Gondi CS. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol Biol Cell. 2013; 24: 2620-2632.
36. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis. 2002; 19: 193-207.
37. Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011; 68: 3853-3868.
38. Keller H, Eggli P. Protrusive activity, cytoplasmic compartmentalization, and restriction rings in locomoting blebbing Walker carcinosarcoma cells are related to detachment of cortical actin from the plasma membrane. Cell Motil Cytoskeleton. 1998; 41: 181-193.
39. Jones JG, Segall J, Condeelis J. Molecular analysis of amoeboid chemotaxis: parallel observations in amoeboid phagocytes and metastatic tumor cells. EXS 1991; 59: 1-16.
40. Montuori N, Visconte V, Rossi G, Ragno P. Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 2005; 93: 192-198.
41. Bernstein AM, Greenberg RS, Taliana L, Masur SK. Urokinase anchors uPAR to the actin cytoskeleton. Invest Ophthalmol Vis Sci. 2004; 45: 2967-2977.
42. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem. 2000; 275: 10228-10234.
43. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood. 2006; 108: 1441-1450.
44. Yue J, Zhang K, Chen J. Role of integrins in regulating proteases to mediate extracellular matrix remodeling. Cancer Microenviron. 2012; 5: 275-283.
45. O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics 2013; 3: 496-506.
46. Gleghorn JP, Pratt ED, Denning D, Liu H, Bander NH, Tagawa ST, Nanus DM, Giannakakou PA, Kirby BJ. Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip. 2010; 10: 27-29.
47. Gutierrez-Juarez G, Gupta SK, Weight RM, Polo-Parada L, Papagiorgio C, Bunch J, Viator JA. Optical Photoacoustic Detection of Circulating Melanoma Cells In Vitro. Int J Thermophys. 2010; 31: 784-792.
48. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996; 273: 1551-1555.